GİZEM DAĞCI

Dr. GİZEM DAĞCI

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Rheumatology International
Verified
Journal Article
Open access
PDF file
MBMurat Bektaş
Murat Bektaş
BÇBilger Çavuş
Bilger Çavuş
BABesim Fazıl Ağargün
Besim Fazıl Ağargün
IŞİbRahim Volkan Şenkal
İbRahim Volkan Şenkal
NKNevzat Koca
Nevzat Koca
AGAhmet Gül
Ahmet Gül
To evaluate the utility of elasticity imaging techniques, such as transient elastography (FibroScan), in assessing the liver and transplanted kidney in patients with AA amyloidosis (AA-A). This study was conducted in patients with AA-A, while patients with immunoglobulin light chain amyloidosis (AL-A), Familial Mediterranean Fever (FMF) without amyloidosis, and healthy controls (HC) were included as comparison groups for liver stiffness (LS) measurements. Additionally, kidney stiffness (KS) was measured in renal transplant recipients (RTRs) with transplants due to AA-A or other causes of chronic renal failure. LS evaluations were performed in 65 patients with AA-A, 14 with AL-A, 20 with FMF, and 27 with HC. LS (kPa) was significantly higher [median (IQR)] in patients with AA-A [6.4 (5.4)] and AL-A [9.8 (11)] compared to HC [4.7 (1.7)] (p < 0.001). However, the difference between AL-A and AA-A was not statistically significant. LS values were comparable in FMF-AA patients with [6.8 (6.6)] and without [5.7 (3.6)] liver involvement, and FMF patients without amyloidosis [7.15 (4.6)]. The median KS values were comparable in 19 AA-A and 16 disease controls. However, KS values were significantly higher in patients with recurrent amyloidosis in the transplanted kidney [29.3 (18.9)] compared to those without recurrence [10.9 (7.7)] (p = 0.003). In our study, increased liver stiffness measurements were observed in patients with AA-A, AL-A, and FMF compared to HC. Transient elastography using FibroScan appears to be a promising non-invasive tool for assessing liver involvement in AA-A and may aid in detecting recurrence of amyloidosis in transplanted kidneys. Further studies are needed to validate the utility of FibroScan in evaluating the involvement of the liver and kidneys in patients with AA-A.

1 January 2025 in Journal of Enterocolitis
Verified
Journal Article
Open access
PDF file
ASAdem Sarıca
Adem Sarıca
AAAlper Akın
Alper Akın
GDGİZEM DAĞCI
GİZEM DAĞCI
The term inflammatory bowel disease (IBD) typically refers to a group of inflammatory gastrointestinal conditions, primarily Crohn’s disease and ulcerative colitis. Colonoscopy remains the gold standard for diagnosing and managing IBD by evaluating mucosal healing. However, instead of relying solely on invasive endoscopy to confirm mucosal healing, biomarkers are frequently used to indicate inflammation in patients with IBD. In recent decades, fecal calprotectin and fecal lactoferrin have received considerable attention for the diagnosis and non-invasive management of IBD. Numerous studies have investigated fecal biomarkers for predicting the endoscopic and histologic activity of IBD, as well as the likelihood of disease recurrence. In this paper, we reviewed original articles and literature reviews on inflammatory markers in adults, published primarily between 2019 and 2024, along with select older studies. Although fecal calprotectin is the most commonly used fecal biomarker in clinical practice, several other potential fecal biomarkers have been described in the literature. After a brief introduction to these biomarkers, we aim to answer the question of which is the most sensitive biomarker of mucosal healing and whether alternatives to fecal calprotectin could be utilized.



16 September 2025 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
GDGİZEM DAĞCI
GİZEM DAĞCI
BÇBilger Çavuş
Bilger Çavuş
ÖAÖrmeci Çiftçibaşı Aslı
Örmeci Çiftçibaşı Aslı

15 May 2026 in Postgraduate Medicine
Verified
Journal Article
Closed access
ZİZülal İstemihan
Zülal İstemihan
AÇAhmet Oğuz Çelik
Ahmet Oğuz Çelik
ATArzu Taş
Arzu Taş
DDDilek Deniz
Dilek Deniz
ÇMÇağrı Muratoğlu
Çağrı Muratoğlu
SKSabahattin Kaymakoğlu
Sabahattin Kaymakoğlu
It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.